European Association for the Study of Diabetes

European Association for the Study of Diabetes Promoting excellence in diabetes care since 1965. The European Association for the Study of Diabetes e.V.
(1)

(EASD) is a membership-based academic non-profit organization. It was founded in 1965 and its headquarters is based in Duesseldorf, Germany. EASD is a networks for diabetologists with active members from all over the world. Membership is open to scientists, physicians, students, postdocs and fellows, allied health professionals and nurses who are interested in the field of diabetes or related dise

ases. The EASD Annual Meeting is one of the largest diabetes conferences in the world, attracting thousands of delegates each year. The scientific programme includes hundreds of talks, presentations and discussions on the latest results from basic and clinical diabetes research. EASD is also a leading player in postgraduate education having trained thousands of healthcare professionals through dedicated training courses and online education activities. Our award winning e-Learning platform, offers free access to courses developed with world-class experts in diabetes research and care. The Association is actively involved in producing and endorsing statements and guidelines translating the latest results from diabetes research into best practices in diabetes management. These statements and guidelines have proven to have significant visibility and substantial impact on health care, particularly when concerning statements on treatment and diagnostic criteria. By creating the Early Career Academy, EASD has increased its commitment to support, train, mentor, and create opportunities for scientists, clinicians, and students who are at an early or intermediate stage of their career. The European Foundation for the Study of Diabetes (EFSD) was founded by EASD in 2000 to stimulate diabetes research in Europe. EFSD offers support in all areas of diabetes research through a wide range of joint and stand-alone initiatives. Funding streams are available throughout the year and since inception, EFSD has committed over €120 million to diabetes research in Europe. EASD is also the publisher of Diabetologia, a major monthly international diabetes journal with an impact factor of 8.2 (2022). The journal publishes original clinical, translational and experimental research on all aspects of diabetes and related subjects. For more information about EASD, please visit: www.easd.org

📢 Have you registered for the upcoming EASD Early Career Academy webinar?! There's still time⏲️Join the Early-Career Aca...
31/07/2025

📢 Have you registered for the upcoming EASD Early Career Academy webinar?! There's still time⏲️

Join the Early-Career Academy and Prof. Peter Rossing (Steno Diabetes Center Copenhagen) for an in-depth look at recent developments in kidney protection and how emerging evidence may help shape treatment approaches to chronic kidney disease (CKD) in type 1 diabetes.

This session builds on the success of kidney protection strategies in type 2 diabetes and will explore how to apply these learnings more broadly in clinical practice.

🗓️21 Aug 2025 |🕛16:30 CEST

🔗 Register now: https://us06web.zoom.us/meeting/register/s6d9UlyISrO37BknGQg1CQ #/registration

📟 New EASD e-Learning journal read: 💉 A new phase II study has tested semaglutide at doses of up to 16 mg per week for p...
30/07/2025

📟 New EASD e-Learning journal read: 💉 A new phase II study has tested semaglutide at doses of up to 16 mg per week for people with type 2 diabetes and obesity – eight times the maximum dose currently approved.

What were the results? More weight loss, modest improvements in glycaemic control and significantly higher rates of gastrointestinal side effects. “The results confirmed the benefit-risk profile of currently approved doses of semaglutide for clinically meaningful glucose and weight management in people with type 2 diabetes,” says first-author Vanita Aroda of Brigham and Women's Hospital.

🔗 Read more on the EASD e-Learning platform: https://easd-elearning.eu/news/451/Higher-than-currently-approved-doses-of-semaglutide-not-justified-for-type-2-diabetes-treatment.html

🔬 Meet Prof. Dr. Anja Zeigerer (Universitätsmedizin Mannheim, Universität Heidelberg), recipient of the   2022 “New Targ...
29/07/2025

🔬 Meet Prof. Dr. Anja Zeigerer (Universitätsmedizin Mannheim, Universität Heidelberg), recipient of the 2022 “New Targets for Diabetes or Obesity-related Metabolic Diseases” Programme, whose research explores how endosomal proteins influence glucose metabolism in type 2 diabetes.

Her team investigated why the endosomal protein Vps37a is reduced in the livers of people with T2D. They found that Vps37a regulates hepatic glucose production by controlling glucagon receptor localization - a key insight into the transcriptional control of metabolism and a potential therapeutic target.

The EFSD award enabled Prof. Dr. Zeigerer to expand her research into novel regulators of glucose metabolism and build collaborations across academia and industry.

📖Read the full study 👉 https://doi.org/10.1016/j.cmet.2022.09.022

💡Explore EFSD opportunities 👉 https://www.europeandiabetesfoundation.org/programmes.html

Programme supported by an educational grant from MSD Invents.

📚 Reading recommendation for the weekend:Browse through the EASD 2025 Final Programme - 300+ pages packed with exciting ...
25/07/2025

📚 Reading recommendation for the weekend:
Browse through the EASD 2025 Final Programme - 300+ pages packed with exciting content, from basic science to clinical diabetes research, cutting-edge technology, education, and more.

Plan ahead for and explore the final programme:
📖https://www.easd.org/uploads/EASD2025_Final-Programme.pdf

🎟️👉 Don’t forget to register: https://www.easd.org/annual-meeting/easd-2025/registration/

23/07/2025

5️⃣A new episode of “5 things we don’t yet know” is out on EASD !

Prof. Luigi Gnudi from King's College London proposes important research questions drawing from challenges he experiences in his own clinical practice regarding:
💊 The latest drug developments
🫘 A possibly new phenotype of kidney disease
🦶 Diabetic foot ulcers

📺 Watch the full episode on EASD e-Learning👉 https://easd-elearning.eu/episode/337/Drugs-phenotype-and-ulcers.html

🔬 Are you perhaps researching in any of these areas?! We’d be curious to know - tell us about your research in the comments below 👇

🏃‍♀️‍➡️🏃‍♀️‍➡️🏃‍♀️‍➡️ Glad to see the momentum going strong ahead of  , with over 5,000 members now part of the 5K@EASD ...
23/07/2025

🏃‍♀️‍➡️🏃‍♀️‍➡️🏃‍♀️‍➡️ Glad to see the momentum going strong ahead of , with over 5,000 members now part of the 5K@EASD Strava Club.

It's inspiring to witness such global engagement and shared commitment to raising awareness through the Virtual Challenge.

Have you signed up yet? Join the movement and be part of this growing community making a difference 👉 https://www.strava.com/clubs/5keasd2025



Novo Nordisk Team Novo Nordisk

Join us for the 5K@EASD Virtual Challenge from 12-17 September, 2025! This year, we are celebrating Novo Nordisk's 20th anniversary of sponsorship of the 5K@EASD. Each year, we come together as a global community to raise diabetes awareness and to raise public awareness about the importance of a hea...

🤝 Meet David Rizo Roca ,(Karolinska Institutet) recipient of the  / Lilly Young Investigator Award, whose research explo...
22/07/2025

🤝 Meet David Rizo Roca ,(Karolinska Institutet) recipient of the / Lilly Young Investigator Award, whose research explores the role of creatine metabolism in type 2 diabetes.

Although creatine is a key energy metabolite, recent studies linked high circulating levels to increased T2D risk. Dr. Rizo Roca’s work showed that modulating creatine levels had minimal effect on insulin sensitivity or glucose homeostasis. Instead, his team identified the mitochondrial enzyme CKMT2 as essential for muscle metabolism. Loss of CKMT2 led to reduced glucose oxidation, mitochondrial dysfunction, and was associated with elevated HbA1c - hallmarks of metabolic disease.

The EFSD award supported Dr. Rizo Roca in developing this independent research path early in his career.

📖 Read the full study👉 https://www.science.org/doi/10.1126/scitranslmed.ado3022

💡Explore more EFSD opportunities👉 https://www.europeandiabetesfoundation.org/programmes.html

Programme supported by Eli Lilly and Company

🚨 Final call!! Applications close soon🚨The European Association for the Study of Diabetes (EASD) and the European Founda...
21/07/2025

🚨 Final call!! Applications close soon🚨

The European Association for the Study of Diabetes (EASD) and the European Foundation for the Study of Diabetes ( ) are looking for a new Junior Scientific Officer (JSO).

If you hold a PhD (or equivalent) in life sciences and want to help shape the future of diabetes research and education in Europe, this is your chance.

🗓 Deadline: Thursday, 24 July 2025
📍 Based in Düsseldorf

🔗 Apply now:https://www.easd.org/uploads/JuniorScientificOfficer_JobAd_2025.pdf

🌐 Learn more: www.easd.org

🚨 We’re hiring! 🚨

Join the European Association for the Study of Diabetes and the European Foundation for the Study of Diabetes (EFSD) as our next Junior Scientific Officer (JSO).

If you're a graduate in life sciences (PhD or equivalent) passionate about advancing diabetes research and fostering international scientific collaboration, we’d love to hear from you.

Your role:
🔬 Support scientific initiatives and grant processes
📝 Help develop educational programmes and e-learning activities
🤝 Engage with our members, collaborators, and key stakeholders
🌍 Contribute to the scientific programme of the EASD Annual Meeting

Apply by 24 July 2025 and help shape the future of diabetes research in Europe.

👉 Find out more & apply:https://www.easd.org/uploads/JuniorScientificOfficer_JobAd_2025.pdf
🔗 Learn about us: www.easd.org

🎧 Catching up on your podcast queue?Our Diabetes Insights - Breakthroughs and Innovators podcast series brings you exper...
18/07/2025

🎧 Catching up on your podcast queue?

Our Diabetes Insights - Breakthroughs and Innovators podcast series brings you expert perspectives on the future of diabetes care - from emerging technologies and beta cell therapies to prevention strategies, policy, and personalised medicine.

📍Listen to all episodes on the EASD Podcast Hub - https://www.easd.org/media-centre/podcasts.html

📺 Dive deeper with full interviews on YouTube - https://www.youtube.com/

Stay informed and inspired until we return with new episodes after !

⏳ Still time to apply!Are you working on cutting-edge basic or clinical diabetes research? Don’t miss your chance to app...
17/07/2025

⏳ Still time to apply!
Are you working on cutting-edge basic or clinical diabetes research? Don’t miss your chance to apply for the and Eli Lilly and Company European Diabetes Research Programme, open to researchers in Europe and associated countries.

✅ Grants of up to €100,000 are available, with the option to request more for exceptional clinical projects with clear justification.
📅 Deadline: 1 September 2025
📍 Submit via the EFSD Programme Portal only

Access the portal, download the templates, and review full submission details here 👉 https://www.europeandiabetesfoundation.org/workshops/78-efsd-and-lilly-european-diabetes-research-programme.html

Let’s drive progress together in diabetes research.

📢 New Funding Opportunity! Applications are now open for the and Eli Lilly and Company European Diabetes Research Programme!

This programme supports innovative basic and clinical diabetes research across Europe and associated countries. Grants of up to €100,000 are available with the option to request more for exceptional clinical projects with clear justification.

📅 Application deadline: 1 September 2025
📍 Applications must be submitted via the new EFSD Programme Portal.

Whether your project addresses autoimmunity, treatment strategies, health outcomes or novel technologies, if it advances diabetes research, we want to hear from you.

Access the portal, download application templates, and review submission guidelines here 👉 https://www.europeandiabetesfoundation.org/workshops/78-efsd-and-lilly-european-diabetes-research-programme.html

Let’s drive progress together in .

⏳Applications close soon! We’re looking for our next Junior Scientific Officer (JSO) to join the European Association fo...
17/07/2025

⏳Applications close soon!

We’re looking for our next Junior Scientific Officer (JSO) to join the European Association for the Study of Diabetes (EASD) and the European Foundation for the Study of Diabetes ( ).

If you hold a PhD (or equivalent) in life sciences and want to contribute to international diabetes research, education, and collaboration - we’d love to hear from you!

🗓 Deadline: 24 July 2025
📍 Location: Düsseldorf, Germany (onsite)

🌐 Apply now:https://www.easd.org/uploads/JuniorScientificOfficer_JobAd_2025.pdf

🔎 Learn more: www.easd.org

🚨 We’re hiring! 🚨

Join the European Association for the Study of Diabetes and the European Foundation for the Study of Diabetes (EFSD) as our next Junior Scientific Officer (JSO).

If you're a graduate in life sciences (PhD or equivalent) passionate about advancing diabetes research and fostering international scientific collaboration, we’d love to hear from you.

Your role:
🔬 Support scientific initiatives and grant processes
📝 Help develop educational programmes and e-learning activities
🤝 Engage with our members, collaborators, and key stakeholders
🌍 Contribute to the scientific programme of the EASD Annual Meeting

Apply by 24 July 2025 and help shape the future of diabetes research in Europe.

👉 Find out more & apply:https://www.easd.org/uploads/JuniorScientificOfficer_JobAd_2025.pdf
🔗 Learn about us: www.easd.org

16/07/2025

💭 How can we use continuous glucose monitoring to intercept or even revert the progression of early dysglycaemia to Type 2 diabetes?

🧠 Diabetes tech expert Prof. Tadej Battelino discusses what he believes is currently one the most exciting diabetes research areas.

📺 Watch our new Expert Insights episode on the EASD e-Learning platform: https://easd-elearning.eu/episode/336/CGM-in-Type-2-Diabetes.html

Adresse

EASD/Rheindorfer Weg 3
Düsseldorf
40591

Öffnungszeiten

Montag 08:00 - 17:00
Dienstag 08:00 - 17:00
Mittwoch 08:00 - 17:00
Donnerstag 08:00 - 17:00
Freitag 08:00 - 17:00

Telefon

+492117584690

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von European Association for the Study of Diabetes erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Die Praxis Kontaktieren

Nachricht an European Association for the Study of Diabetes senden:

Teilen

Our Story

The Active Membership of the Association currently numbers more than 4,000 individuals from over 100 countries throughout the world. The Association also bestows Honorary Membership on any individual whose medical or scientific contribution to diabetes research has been outstanding; the first Honorary Member of the Association was Charles Best. The Association is governed by an Executive Committee chaired by the President. The Annual Meeting of the Association is held in a different European city each year. Abstracts are invited from members as well as non-members. All abstracts are anonymously reviewed by a Programme Committee, chaired by the Honorary Secretary. The EASD was one of the first international Associations to introduce the anonymous review of abstracts. The high quality of scientific research presented at the Annual Meetings is attested to by the increasing participation. The scientific programme of the Meeting, providing titles of the lectures and symposia, is made available online at a very early stage. Once confirmed, the speakers' names are made available and before the start of the Meeting all abstracts accepted for presentation can be accessed online. A search function assists the visitor in finding abstracts in their field of interest. Webcasts, poster presentations from the EASD Annual Meeting can be accessed via the EASD website.

EASD Postgraduate Education Courses have been organised by the Association since 1972 and, since then, over 25,000 medical professionals have taken part.

In 1999, the EASD increased its commitment to stimulate diabetes research in Europe by creating the European Foundation for the Study of Diabetes (EFSD).

Since its inception, EFSD has committed over Euro 100 million to diabetes research in Europe by various funding means.